Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin B Kim

Showing results (81-90 of 134) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanomaPatrick A Ott, Omid Hamid, Anna C Pavlick, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionIgor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.
BMC Cancer|April 29, 2018
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapiesElham Vosoughi, Jee Min Lee, James R Miller, et al.
Melanoma Research|July 9, 2011
A phase II study of gefitinib in patients with metastatic melanomaSapna P Patel, Kevin B Kim, Nicholas E Papadopoulos, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 13, 2022
A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal MelanomaDavid R Minor, Kevin B Kim, Ricky T Tong, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 2009
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal typeCarlos A Torres-Cabala, Wei-Lien Wang, Jonathan Trent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanomaKevin B Kim, Jeffrey A Sosman, John P Fruehauf, et al.
Cancer|December 20, 2011
NRAS mutation status is an independent prognostic factor in metastatic melanomaJohn A Jakob, Roland L Bassett, Chaan S Ng, et al.
Cancer|August 12, 2020
Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging systemMohammed Kashani-Sabet, James R Miller, Serigne Lo, et al.
American Journal of Clinical Oncology|March 7, 2018
Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the LiverJesus Vera-Aguilera, Agop Y Bedikian, Roland L Bassett, et al.
Pageof 14

Showing results (81-90 of 134) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanomaPatrick A Ott, Omid Hamid, Anna C Pavlick, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionIgor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.
BMC Cancer|April 29, 2018
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapiesElham Vosoughi, Jee Min Lee, James R Miller, et al.
Melanoma Research|July 9, 2011
A phase II study of gefitinib in patients with metastatic melanomaSapna P Patel, Kevin B Kim, Nicholas E Papadopoulos, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 13, 2022
A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal MelanomaDavid R Minor, Kevin B Kim, Ricky T Tong, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 2009
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal typeCarlos A Torres-Cabala, Wei-Lien Wang, Jonathan Trent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanomaKevin B Kim, Jeffrey A Sosman, John P Fruehauf, et al.
Cancer|December 20, 2011
NRAS mutation status is an independent prognostic factor in metastatic melanomaJohn A Jakob, Roland L Bassett, Chaan S Ng, et al.
Cancer|August 12, 2020
Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging systemMohammed Kashani-Sabet, James R Miller, Serigne Lo, et al.
American Journal of Clinical Oncology|March 7, 2018
Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the LiverJesus Vera-Aguilera, Agop Y Bedikian, Roland L Bassett, et al.
Pageof 14